Artículo

Classical membrane progesterone receptors in murine mammary carcinomas: agonistic effects of progestins and RU-486 mediating rapid non-genomic effects

Bottino, Maria Cecilia Icon; Cerliani, Juan Pablo Icon; Rojas, Paola Andrea Icon; Giulianelli, Sebastian Jesus Icon; Soldati, Rocío Cinthia ; Mondillo, Carolina Icon; Gorostiaga, Maria Alicia Icon; Pignataro, Omar Pedro Icon; Calvo, Juan Carlos Icon; Gutkind, Jorge Silvio ; Amornphimoltham, Panomwat ; Molinolo, Alfredo Icon; Luthy, Isabel Alicia Icon; Lanari, Claudia Lee Malvina Icon

Otros responsables

Fecha

04/2010

Editorial

Springer

Revista

Breast Cancer Research and Treatment

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

0167-6806

eISSN

1573-7217

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

In this article, we demonstrate the expression of functional progesterone binding sites at the cell membrane in murine mammary carcinomas that are stimulated by progestins and inhibited by antiprogestins. Using confocal immunofluorescence, ligand binding and cell compartment-specific western blots, we were able to identify the presence of the classical progesterone receptors. Medroxyprogesterone acetate (MPA) and RU-486 (1 × 10(-11) and 1 × 10(-8) M) behaved as agonists activating extracellular signal-regulated kinases (ERKs) and progestin-regulated proteins, except for Cyclin D1 and Tissue factor which failed to increase with 1 × 10(-8) M RU-486, an experimental condition that allows PR to bind DNA. These results predicted a full agonist effect at low concentrations of RU-486. Accordingly, at concentrations lower than 1 × 10(-11) M, RU-486 increased cell proliferation in vitro. This effect was abolished by incubation with the ERK kinase inhibitor PD 98059 or by OH-tamoxifen. In vivo, at a daily dose of 1.2 μg/kg body weight RU-486 increased tumor growth, whereas at 12 mg/kg induces tumor regression. Our results indicate that low concentrations of MPA and RU-486 induce similar agonistic non-genomic effects, whereas RU-486 at higher concentrations may inhibit cell proliferation by genomic-induced effects. This suggests that RU-486 should be therapeutically administered at doses high enough to guarantee its genomic inhibitory effect.

Colecciones

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa